Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year.
Nurix Therapeutics: Q4 Earnings Insights
Nurix Therapeutics (NASDAQ:NRIX) reported its Q4 earnings results on Thursday, January 27, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
60 Biggest Movers From Yesterday
Gainers
Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
Nurix Therapeutics Announced UK Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presented New Preclinical Data at ASH 2021; Said Anticipates Dosing First Patient in H1 2022
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the grant of a Clinical Trial Authorization (CTA) for NX-5948, a potent and selective degrader of Bruton's tyrosine kinase (BTK) and the second drug candidate in Nurix's BTK degradation program.
Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?
SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ:NRIX) to $64 from $50, with an Outperform rating, seeing an…
Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial
Nurix Therapeutics Inc (NASDAQ:NRIX) announced initial data from Phase 1a trial of NX-2127 in relapsed or refractory B cell malignancies. Initial…